AIM: Human embryonic stem cells (hESCs) represent a novel cell source to treat diseases such as heart failure and for use in drug screening. In this study, we aim to promote efficient generation of cardiomyocytes from hESCs by combining the current optimal techniques of controlled growth of undifferentiated cells and specific induction for cardiac differentiation. We also aim to examine whether these methods are scalable and whether the differentiated cells can be cryopreserved. METHODS & RESULTS: hESCs were maintained without conditioned medium or feeders and were sequentially treated with activin A and bone morphogenetic protein-4 in a serum-free medium. This led to differentiation into cell populations containing high percentages of cardiomyocytes. The differentiated cells expressed appropriate cardiomyocyte markers and maintained contractility in culture, and the majority of the cells displayed working chamber (atrial and ventricular) type electrophysiological properties. In addition, the cell growth and differentiation process was adaptable to large culture formats. Moreover, the cardiomyocytes survived following cryopreservation, and viable cardiac grafts were detected after transplantation of cryopreserved cells into rat hearts following myocardial infarctions. CONCLUSION: These results demonstrate that cardiomyocytes of high quality can be efficiently generated and cryopreserved using hESCs maintained in serum-free medium, a step forward towards the application of these cells to human clinical use or drug discovery.
AIM: Human embryonic stem cells (hESCs) represent a novel cell source to treat diseases such as heart failure and for use in drug screening. In this study, we aim to promote efficient generation of cardiomyocytes from hESCs by combining the current optimal techniques of controlled growth of undifferentiated cells and specific induction for cardiac differentiation. We also aim to examine whether these methods are scalable and whether the differentiated cells can be cryopreserved. METHODS & RESULTS: hESCs were maintained without conditioned medium or feeders and were sequentially treated with activin A and bone morphogenetic protein-4 in a serum-free medium. This led to differentiation into cell populations containing high percentages of cardiomyocytes. The differentiated cells expressed appropriate cardiomyocyte markers and maintained contractility in culture, and the majority of the cells displayed working chamber (atrial and ventricular) type electrophysiological properties. In addition, the cell growth and differentiation process was adaptable to large culture formats. Moreover, the cardiomyocytes survived following cryopreservation, and viable cardiac grafts were detected after transplantation of cryopreserved cells into rat hearts following myocardial infarctions. CONCLUSION: These results demonstrate that cardiomyocytes of high quality can be efficiently generated and cryopreserved using hESCs maintained in serum-free medium, a step forward towards the application of these cells to human clinical use or drug discovery.
Authors: Christine Mummery; Dorien Ward-van Oostwaard; Pieter Doevendans; Rene Spijker; Stieneke van den Brink; Rutger Hassink; Marcel van der Heyden; Tobias Opthof; Martin Pera; Aart Brutel de la Riviere; Robert Passier; Leon Tertoolen Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Jennifer C Moore; Jidong Fu; Yau-Chi Chan; Dawei Lin; Ha Tran; Hung-Fat Tse; Ronald A Li Journal: Biochem Biophys Res Commun Date: 2008-05-27 Impact factor: 3.575
Authors: Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson Journal: Science Date: 2007-11-20 Impact factor: 47.728
Authors: Ralph Graichen; Xiuqin Xu; Stefan R Braam; Thavamalar Balakrishnan; Siti Norfiza; Shirly Sieh; Set Yen Soo; Su Chin Tham; Christine Mummery; Alan Colman; Robert Zweigerdt; Bruce P Davidson Journal: Differentiation Date: 2007-11-15 Impact factor: 3.880
Authors: Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry Journal: Nat Biotechnol Date: 2007-08-26 Impact factor: 54.908
Authors: Lei Yang; Mark H Soonpaa; Eric D Adler; Torsten K Roepke; Steven J Kattman; Marion Kennedy; Els Henckaerts; Kristina Bonham; Geoffrey W Abbott; R Michael Linden; Loren J Field; Gordon M Keller Journal: Nature Date: 2008-04-23 Impact factor: 49.962
Authors: André Tomescot; Julia Leschik; Valérie Bellamy; Gilbert Dubois; Emmanuel Messas; Patrick Bruneval; Michel Desnos; Albert A Hagège; Michal Amit; Joseph Itskovitz; Philippe Menasché; Michel Pucéat Journal: Stem Cells Date: 2007-05-31 Impact factor: 6.277
Authors: Nimalan Thavandiran; Nicole Dubois; Alexander Mikryukov; Stéphane Massé; Bogdan Beca; Craig A Simmons; Vikram S Deshpande; J Patrick McGarry; Christopher S Chen; Kumaraswamy Nanthakumar; Gordon M Keller; Milica Radisic; Peter W Zandstra Journal: Proc Natl Acad Sci U S A Date: 2013-11-19 Impact factor: 11.205
Authors: Katrina J Hansen; John T Favreau; Joshua R Gershlak; Michael A Laflamme; Dirk R Albrecht; Glenn R Gaudette Journal: Tissue Eng Part C Methods Date: 2017-06-27 Impact factor: 3.056